Biotechnology from bench to business

• Follow GEN on:
• Login | Register | Subscribe

• ADME/Tox
• Automation
• Bioprocess Scale-Up
• Bioreactors
• Biosimilars
• Cell Culture
• Cell-Based Assays
• Contract Manufacturing
• Gene Therapy
• High-Throughput Screening
• Immunoassay
• Induced Pluripotent Stem Cells
• Informatics
• Liquid Handling
• Pharmacokinetics
• Protein Characterization
• Protein Detection
• Regenerative Medicine
• Sequencing
• Stem Cells
• Western Blot

Patricia Fitzpatrick Dimond, Ph.D.

Patricia Fitzpatrick Dimond, Ph.D. (pdimond@genengnews.com), is technical editor at GEN.

More GEN Content From This Contributor

GEN Articles

• Insight & Intelligence™: FDA Speeds Things Up
• Insight & Intelligence™: CRISPR/Cas Comes of Age–Almost
• Insight & Intelligence™: Targeting Deranged Metabolism to Treat Cancer
• Insight & Intelligence™: Acquired Drug Resistance in Cancer
• Insight & Intelligence™: Is Brain Mapping Ready for Big Science?
• Feature Articles: The Search for Depression Biomarkers
• Feature Articles: Leveraging Synthetic Lethality for Cancer
• Feature Articles: Clinical Application of miRNAs a Ways Off
• BioMarket Trends: Regulatory Environment Warms Up to Obesity Drugs
• Feature Articles: Immune Response Markers for Cancer Vaccines
• BioMarket Trends: FDA Releases Biosimilars Guidelines to Little Fanfare
• Insight & Intelligence™: Syn Bio Delivers Cool Tools but Drugs Are a Ways Off
• Feature Articles: Two Technologies Are Better Than One
• Feature Articles: Antibiotic Quagmire Demands Creativity
• Feature Articles: Regenerative Medicine Stays Its Course
• BioMarket Trends: Finding a Blockbuster Successor to Lipitor
• BioMarket Trends: Multigene Testing for Cancer Evaluation
• Feature Articles: Capitalizing on Cell-Signaling Advances
• Feature Articles: Parkinson Disease Research in Doldrums
• Feature Articles: Biological Scaffolds for ReGen Medicine
• Feature Articles: RNAi Approaches for Target Validation
• Feature Articles: Cell Signaling Pathway Analysis
• Feature Articles: Transforming Transfection Technology
• Feature Articles: Revamping Drug Discovery Strategies
• Feature Articles: Optimizing the Profiling of Protein Kinases
• Feature Articles: Advances in Label-Free Assay Screening
• Feature Articles: Delivery Firms Focus on Efficiency & Efficacy
• Feature Articles: Creating Therapies via the RNAi Route
• Feature Articles: Advances in Quantitative Proteomics
• Feature Articles: Fighting Pancreatic Cancer's Intractable Nature
• Wall Street BioBeat: Antidepressant Efficacy Called into Question
• Feature Articles: miRNAs' Therapeutic Potential
• Feature Articles: Hopes Dashed for Alzheimer's Patients
• Feature Articles: Drug Repositioning Gains in Popularity
• + Show More- Show Less

Insight & Intelligence™

• Bugs and the Body
• Bacteria from Lean Humans Can Slim Obese Mice
• FDA Speeds Things Up
• Shark Antibodies: Bigger Than Jaws
• Getting Ready for the Flu
• What Junk DNA? It’s an Operating System
• Do VSELs Hold Water?
• CRISPR/Cas Comes of Age—Almost
• Closer-to-Real 3D Cell Culture Advances
• Gene Editing to Treat Genetic Diseases, Part II
• Flexibility in Biopharmaceutical Manufacturing Capacity
• Gene Editing with Multiple Molecular Means
• Metagenomics May Hold Key to Novel Antibiotic Discovery
• Targeting Deranged Metabolism to Treat Cancer
• Moving Genomics Closer to the Clinic
• The Tumor Microenvironment as a Drug Target, Part II
• The Tumor Microenvironment as a Drug Target: Chasing Slippery Targets
• Detecting Acquired Drug Resistance in Cancer
• Performing “Informative Clinical Trials” in Mice
• Bird Flu Back Again?
• Women and Smoking
• Is Brain Mapping Ready for Big Science?
• DNA to Hang Your Hat On
• Biosimilars: Not So Far So Fast
• Isothermal PCR Gets Off The Dime
• Bioprinting in 3D
• DNA Methylation Rules: Studying Epigenetics with New Tools
• New Life for Embryonic Stem Cells
• Transgenic Salmon Prove Tough to Tackle
• Building a Self-Destructive Mosquito
• Hearing Better Through Chemistry
• Costly Cats: Dispelling Allergies-to-Animals Mythology
• Drug Companies Exert Greater Influence on Development
• Genome Testing Reduces Overtreatment
• The Long and the Short of DNA Sequencing
• Getting Cancer Immunotherapeutics Approved
• In Vitro Clinical Trials: Not that Far-Fetched
• Prizes and Quackery Dominate iPS Cell News
• End-Running Cancer Resistance to Targeted Therapies
• The Search for Depression Biomarkers
• Oncogene Addiction: Real or Not?
• Leveraging Synthetic Lethality for Cancer Therapeutics
• Building a Rat That Swims Like a Jellyfish
• Combined with Other Technologies, Combinatorial Chemistry Remains Relevant
• Clinical Application of miRNAs Remains a Ways Off
• CMOs Capitalizing on Experience to Develop Their Own Therapeutics
• Why Biomarker Discovery Is Hard
• Leveraging the Cancer Transcriptome for New Drug Targets
• Enabling the Future of Plant Biology
• With Oligonucleotide Drugs, Antisense Arrives but RNAi Has a Long Way to Go
• Autologous Immunotherapy Updates at ASCO Further Define Antitumor Immune Responses
• This Time Last Year: Diagnostic Deals, mAb Therapeutics, and Obesity Drug Development
• Bio-Rad Squashes Idea That the Company Is Up for Grabs
• Stakeholders Share Data to Design Better Trials for Neurodegenerative Diseases
• Researchers Looking for Drug Candidates Tap into the Final Frontier: The Sea
• This Month Last Year: Shire and Thermo Fisher’s Acquisitions and Geron’s hESC Plans
• Researchers Try to Answer the Question: Is Big Data Too Big?
• Firms Are Trying to Untangle Alzheimer Drug Development with mAbs
• Review of Research with Chimpanzee Models Points to Few Areas of Need
• Search for New Analgesics Worth the Pain Given Side Effects of Opioids
• Recent Fear and Loathing in Synthetic Biology Reminiscent of Other Biotechnologies
• Regulatory Environment Warms Up to Obesity Drugs and Could Heat Up Market
• Will Roche Really Drop Illumina and Seek out Another Sequencing Firm?
• Roche, Illumina Duke It Out in Potential $5.7B Takeover Deal
• Immune Response Markers for Cancer Vaccines Paint a Clearer Picture
• How Provenge Laid the Groundwork for Developing and Regulating Cancer Vaccines
• Sequencing Firms Set Up Centers to Advance Genomics Research and Instrument Sales
• What Will FDA Biosimilars Guidelines Mean for Industry?
• Standardization Key to Taking Next-Generation Sequencing to the Next Level
• FDA New Drug Approvals in 2011 Outpace Recent Past
• R&D Direction in 2012 for Sequencing Technologies Is Aimed at Clinical Medicine
• This Year’s M&As Among Life Science Tool Firms Show Interest in Molecular Diagnostics
• Firms Are Upping the Stakes on mAb Biosimilar Development
• Vaccine Isotype Seems to Affect Clinical Outcome in Blood Cancer Trials
• Exome Sequencing Finds Sweet Spot Between Whole-Genome and Targeted Sequencing
• Where Does Geron’s Exit from Embryonic Stem Cells Leave the Field?
• Personalized Medicine Initiatives Step Into the Cloud to Speed Up R&D
• Latest Gene Therapy Disapproval Points to Confusion over Regulatory Setup
• Does Clinical Success Mean Commercial Success for Cancer Vaccines?
• Genomic Studies Are Adding to Evidence of Autism’s Highly Complex Nature
• Studies of Pathways Involved in Alcohol Metabolism Reveal Links to Cancer
• Synthetic Biology Delivers Cool Tools but New Therapeutics Are a Ways Off
• Instrumentation Firms Give Sugar Its Due, Developing Tools for Glycan-Protein Interaction Analysis
• Companies Look for the Practical Approach to Systems Biology
• Recent Research Highlights Cancer Stem Cells as Moving Targets
• Clinical Successes and New Technologies Revive Gene Therapy
• Combining Gene and Cell Therapy Is Arming Researchers with More Options for Cancer
• Exploring Biology in Space May See a Slowdown with the End of NASA’s Shuttle Missions
• Secrecy Surrounds the Development of Tests to Detect Doping
• Companies with Cancer Therapeutic Candidates Ramp Up Companion Diagnostic Efforts
• Growth Strategies for Tool Companies—Acquisition or R&D?
• Cloud Computing Augments Clinical Trial Process
• Biotechs Nail Down Sequence of Elusive E. coli
• Are Early Clinical Successes Enough to Bring RNAi Back from the Brink?
• Biotechnology Instruments Being Used to Detect Alien Life
• Protein Kinase Inhibitors for CNS Diseases at the Research and Discovery Phase
• Biotechs Hop on Cloud Nine with Better Resources Gained from New Technology
• Exploring New Ways to Get at Old Bacterial Targets to Combat Resistant Strains
• To Battle Super-Bugs, Antibiotic R&D Needs to Be Re-Incentivized
• Japan Disaster Renews Interest in Antiradiation Drug Development
• Back to the Future with Somatic Progenitor Cells
• High-Tech Companies Buy Into Biomanufacturing
• Arresting Disorderly Proteins for Disease Treatment
• Timing Is Everything in Studying Disorderly Proteins
• What’s Wrong with Phase II Trials?
• Tumor Cells Back in Circulation for Monitoring Cancer
• Will Antibody Biosimilars See the Light of Day?
• Beckman Coulter on the Chopping Block?
• What Will Succeed Lipitor as the Next Blockbuster Cholesterol-Lowering Drug?
• Getting Personal: Multigene Testing for Individual Cancer Evaluation
• More Pain for Pfizer: Finding Relief in Different Targets
• Melanoma Cells: All Stem Cells in Disguise?
• The Problem of Insufficient Reporting and Publication Bias
• Weighing the Benefits of Rituximab Maintenance Therapy for FL
• Tales from the Biotech Crypt: Sam Waksal Is Back in Business
• Is Avastin Roche’s Achilles Heel?
• Will a Nonautologous Cancer Vaccine Be the Next to Make It Through Approval?
• What Comes After Dendreon’s Provenge?
• Innovations in Peptide Structure Pushing Candidates through Development
• Amgen’s Biomarker Research Underlies Vectibix’ Success
• Could Stapling Revive Peptide Therapeutics?
• No New Parkinson Disease Drug Expected Anytime Soon
• Human Genome Redux: Just a Numbers Game?
• Nanotechnology Enables Precise Cancer Targeting
• Synthetic Biology—The Devil Is in the Financial Details
• Can Microbes Help Stem the BP Oil-Spill Disaster?
• Medical Uses for Marijuana No Longer in the Weeds
• Is the Progression of Adult Stem Cell Therapies into the Clinic a Good Sign for Technology?
• Osiris’ Race to Market an FDA-Approved Stem Cell Product
• Addressing the Needs of Huntington Disease Patients
• PEPs Gaining FDA Nod but Remain Hard to Take
• Avastin: Time for a Predictive Test
• Strong Phase II NSCLC Trial Data Still Not Translating into Phase III Successes
• Lupus Drug Development Remains Risky Business
• Ocrelizumab: One Size Does Not Fit All
• Hopes Dashed for Alzheimer’s Patients Once Again
• Antibody-Drug Conjugates Stage a Comeback
• Antibody-Drug Conjugates to Fight Cancer
• Examining Both Sides of the Sirtuin Coin
• Sirtuins: Antiaging Medicines or Marketing?
• Roche Takes a Stab at Getting mAbs Under the Skin
• Cancer Cell Line Identity Crisis
• Stem Cell Utility Limited by Lack of Ethnic Diversity
• Part 2—Finding Newer Molecular Targets for Antidepressants
• Part 1—Questions Remain about Whether Antidepressants Really Work
• Big Pharma Adopting Orphan Drug Strategy
• Obesity Therapies Show Lackluster Efficacy Results
• Poniard’s Fortunes Likely Rest on Picoplatin
• Refocusing on Therapeutic Protein Production in Plants
• Making Sense of Antisense and Its Rebound Potential
• Confusing Choices for Doctors and Type 2 Diabetes Patients
• Jumping On Genetic Testing—The War of the SNPs
• Clinical Trial Failures Further Signal Pancreatic Cancer’s Intractable Nature
• Biogen Idec and Facet—Following the Money
• Chasing the Therapeutic Potential of miRNAs
• Geron’s Setback with Testing Its hESC Therapy in Humans Points to FDA’s Continued Cautionary Stance
• Dendreon’s $70M Investment in Production Capabilities Could Woo Firms without Similar Expertise
• AIDS Vaccine Development Will Rely on Blind Guesses—At Least for Now
• Need for Novel Approaches to Treating HIV Still Exists
• Companies Step In to Fill Gap in Enzyme Replacement Therapy for Gaucher’s
• Sutent—Would Biomarkers Have Helped?
• Genzyme Plant Shutdown Could Mean up to $300M in Lost Sales
• Denosumab—Great Expectations for Amgen and Osteoporosis Market
• Genentech Goes Beyond Antibodies with Bayhill Therapeutics Diabetes Deal
• Customized Cancer Vaccines Finally (Maybe) Arrive
• + Show More- Show Less